Drug intelligence / Profile preview

WSK-V101K

Development stage: Unknown
Lead developer: Chengdu Weisk Biopharmaceutical
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

WSK-V101K is a recombinant protein subunit vaccine developed by WestVac Biopharma for the prevention of COVID-19. It is specifically designed as a booster vaccine targeting the SARS-CoV-2 Omicron variant, specifically the LP.8.1 lineage. The vaccine is produced using an insect cell expression system and is intended to provide updated protection against circulating variants. It has been evaluated in Phase III clinical trials in Japan as a booster dose in previously vaccinated adults, comparing its safety and immunogenicity to the protein-based vaccine Nuvaxovid.

Other names: WSK-V101K (Omicron LP.8.1)

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on WSK-V101K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V101K.

Explore the full profile